Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer.
Frontiers in pharmacology（2023）
摘要
OPINION article Front. Pharmacol., 06 June 2023Sec. Renal Pharmacology Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1170796
更多查看译文
关键词
von Hippel Lindau factor, hypoxia inducible factor (HIF), renal cancer, prolyl hydroxylase inhibitor (roxadustat), renal anemia, erythropoietin producing cell
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要